--- title: "Balchem | 8-K: FY2025 Q4 Revenue Beats Estimate at USD 263.62 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/276442357.md" datetime: "2026-02-20T12:40:56.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/276442357.md) - [en](https://longbridge.com/en/news/276442357.md) - [zh-HK](https://longbridge.com/zh-HK/news/276442357.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/276442357.md) | [繁體中文](https://longbridge.com/zh-HK/news/276442357.md) # Balchem | 8-K: FY2025 Q4 Revenue Beats Estimate at USD 263.62 M Revenue: As of FY2025 Q4, the actual value is USD 263.62 M, beating the estimate of USD 259.59 M. EPS: As of FY2025 Q4, the actual value is USD 1.21, beating the estimate of USD 1.175. EBIT: As of FY2025 Q4, the actual value is USD 52.29 M. #### Fourth Quarter 2025 Financial Performance - **Net Earnings**: GAAP net earnings were $39.2 million, marking a 16.8% increase compared to the prior year quarter. Adjusted net earnings were $42.338 million, up from $36.876 million in the prior year quarter . - **Adjusted EBITDA**: Adjusted EBITDA reached $67.9 million, an 8.1% increase from the prior year quarter . - **Gross Margin**: Consolidated quarterly gross margin was $93.9 million, an increase of 8.8% compared to $86.3 million in the prior year period. Gross margin as a percentage of sales decreased by 40 basis points to 35.6% from 36.0% in the prior year period, primarily due to higher manufacturing input costs . - **Operating Expenses**: Operating expenses for the quarter were $41.6 million, an increase of $2.7 million from the prior year comparable quarter, mainly due to higher compensation-related expenses. Excluding non-cash amortization of intangible assets, operating expenses were $38.0 million, or 14.4% of sales . - **Net Interest Expense**: Net interest expense was $1.9 million, down from $2.8 million in the prior year quarter, attributed to lower outstanding borrowings and interest rates . - **Effective Tax Rate**: The effective tax rate for the quarter was 21.6%, a decrease from 24.5% in the prior year, primarily due to a decrease in certain foreign taxes . - **Cash Flow**: Cash flows from operations were $67.3 million, and free cash flow was $51.2 million . #### Full Year 2025 Financial Performance - **Net Earnings**: GAAP net earnings were $154.8 million, representing a 20.5% increase from the prior year. Adjusted net earnings were $167.9 million, an increase of 17.4% from the prior year . - **Adjusted EBITDA**: Adjusted EBITDA was $274.9 million, a 9.8% increase from the prior year . - **Cash Flow**: Cash flows from operations were $216.6 million, and free cash flow was $173.6 million . #### Fourth Quarter 2025 Segment Revenue - **Human Nutrition and Health**: Sales were $166.1 million, an increase of $18.8 million or 12.7% compared to the prior year quarter, driven by higher sales in both nutrients and food ingredients businesses . - **Animal Nutrition and Health**: Sales were $61.2 million, an increase of $2.8 million or 4.9% compared to the prior year quarter, due to higher sales in ruminant and monogastric species markets . - **Specialty Products**: Sales were $34.8 million, an increase of $2.0 million or 6.0% compared to the prior year quarter, driven by higher sales in the performance gases business . - **Other**: Sales were $1.544 million . #### Fourth Quarter 2025 Segment Earnings from Operations - **Human Nutrition and Health**: Earnings from operations were $36.8 million, an 8.9% increase, primarily due to higher sales and a favorable mix. Adjusted earnings from operations were $40.0 million, an increase of 9.6% . - **Animal Nutrition and Health**: Earnings from operations were $6.2 million, an 8.6% increase, primarily due to higher sales and a favorable mix. Adjusted earnings from operations were $6.5 million, an increase of 9.2% . - **Specialty Products**: Earnings from operations were $10.5 million, a 5.5% increase, driven by higher sales. Adjusted earnings from operations were $11.6 million, an increase of 6.0% . - **Other and Unallocated**: Earnings from operations were - $1.206 million . #### Balance Sheet and Cash Flow Activities (as of December 31, 2025) - **Net Working Capital**: Net working capital was $189.2 million . - **Cash and Cash Equivalents**: Cash balance was $74.6 million . - **Outstanding Debt**: Outstanding debt on the revolving loan was $164.0 million . - **Net Debt**: Net debt was $89.4 million, with an overall leverage ratio of 0.3 times on a net debt basis . - **Significant Cash Payments (Q4)**: During the quarter, significant cash payments included $53.6 million for common stock repurchases, $16.2 million for capital expenditures and intangible assets acquired, and $8.1 million for income taxes paid . - **Full Year Cash Flow Activities**: Net cash used in investing activities was - $43.891 million. Net cash used in financing activities was - $152.810 million, including principal payments on revolving debt of - $114.0 million, dividends paid of - $28.287 million, and repurchases of common stock of - $107.636 million . #### Outlook 拜切公司 (Balchem Corporation) anticipates continued strong performance and expects ongoing above-market growth for shareholders in 2026 and beyond. The company’s leadership expressed excitement about the future and its strong positioning . ### Related Stocks - [Balchem Corporation (BCPC.US)](https://longbridge.com/en/quote/BCPC.US.md) ## Related News & Research - [Balchem Corporation to Announce Fourth Quarter and Full Year Financial Results](https://longbridge.com/en/news/275121264.md) - [Cintas (CTAS) Valuation Check After Q3 Results And Higher Fiscal 2026 Guidance](https://longbridge.com/en/news/281225115.md) - [Wealth First Promoters Confirm 74% Stake With No Encumbrance in FY26](https://longbridge.com/en/news/281530653.md) - [Key facts: Bunge Increases Securitization to $2.0B; 8-K on Obligation](https://longbridge.com/en/news/281659964.md) - [Firefly Aerospace's Marc Weiser resigns from board](https://longbridge.com/en/news/281662054.md)